Last updated on November 2019

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time) | Hemorrhage | Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation | Acute Bleeding on Long-Term Anticoagulation Therapy
  • Age: Between 18 - 125 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Chronic anticoagulation with warfarin and initial INR 2
  • Emergent bleeding (i.e. intracranial hemorrhage, gastrointestinal hemorrhage, urgent invasive procedures, etc.) or urgent surgery requiring reversal of INR to 1.5

Exclusion Criteria:

  • Younger than 18 years of age
  • History of heparin-induced thrombocytopenia (HIT)
  • Patients without initial or post-administration INR readings
  • Patients with an initial INR <2
  • Pregnant patients
  • Prisoners

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.